The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in EuropeGlobeNewsWire • 12/16/22
Y-mAbs Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmNewsfile Corp • 12/02/22
Y-mAbs Therapeutics receives 'Neutral' stance from Wedbush after FDA rejection of its pediatric cancer drug applicationProactive Investors • 12/02/22
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License ApplicationGlobeNewsWire • 12/01/22
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 11/08/22
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/07/22
Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 11/07/22
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Y-mAbs Therapeutics (YMAB) With Significant Losses to Contact the Firm's Attorneys, Firm Investigating Possible Securities Law ViolationsNewsfile Corp • 11/04/22
Y-mAbs Therapeutics Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmNewsfile Corp • 11/03/22
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 11/03/22
Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022GlobeNewsWire • 11/02/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 11/01/22
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – YMABBusiness Wire • 10/31/22
Y-mAbs Therapeutics shares fall 42% following last week's FDA advisory committee voteMarket Watch • 10/31/22
INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 10/28/22
Wolf Popper LLP Announces Investigation on Behalf of Investors in Y-mAbs Therapeutics, IncNewsfile Corp • 10/27/22
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 10/27/22